Ikonisys SA ALIKO
EURONEXT · France · Health Technology
€1.45+0.05 (+3.57%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
PARIS, September 21, 2026--Regulatory News: ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, announces that its wholly-owned US subsidiary has reached a settlement resolving an existing dispute, pursuant to which it will receive a payment of USD 2 million.The related proceedings have been dismissed.
PARIS, September 15, 2026--Regulatory News: ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, announces the launch of the Probantes project in Brazil, the ongoing incorporation of Probantes Ltda, a new Brazilian business unit wholly owned by Aliko Scientific Srl, and the signing of a strategic industrial cooperation agreement with Biodetecta – Life Science Ltda.
PARIS, September 07, 2026--Regulatory News: ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, announces the successful launch of its collaboration with Partner International Inc., aimed at accelerating the Group’s development, notably in the United States, on the occasion of the ADLM 2026 exhibition in Anaheim, California.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.